Northway Biotech Opens €61M Cell Therapy CDMO in Vilnius with 20 cGMP Lines
- Northway Biotech inaugurated a 3,500-square-meter cell therapy CDMO facility in Vilnius, Lithuania, backed by €61 million investment from Northway Group.
- The center operates up to 20 independent cGMP manufacturing lines for autologous and allogeneic cell therapies, personalized vaccines, and regenerative medicine, with first customers already contracted.
- Facility includes segregated manufacturing infrastructure, quality control labs, and cleanroom systems designed to handle multiple cell-based products in parallel while maintaining contamination control.
Operational Impact
Northway Biotech's Vilnius facility adds 20 parallel cGMP cell-therapy manufacturing lines in Eastern Europe with immediate customer demand, expanding regional capacity for autologous/allogeneic therapies and personalized vaccines.
Source: PharmaSource RSS